DUBLIN--(BUSINESS WIRE)--The "Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)?" report has been added to ResearchAndMarkets.com's offering.
This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- The author estimates that in 2017, there were 177.3 million prevalent cases of attention deficit hyperactivity disorder (ADHD) in people aged 5-44 years worldwide, and forecasts that number to increase to 187.4 million prevalent cases by 2026.
- Approved drugs in the ADHD space target dopamine, dopamine reuptake, norepinephrine (noradrenaline), norepinephrine (noradrenaline) reuptake/transporter, and the alpha 2 adrenergic receptor. The vast majority of approved therapies are administered via the oral route.
- The largest proportion of industry-sponsored drugs in active clinical development for ADHD are in Phase III. Therapies in mid-to-late-stage development for ADHD focus on a wide variety of targets. The majority of pipeline drugs in mid to-late-stage development are administered via the oral route, with only one drug also being tested in intramuscular and subcutaneous formulations.
- High-impact upcoming events for drugs in the ADHD space comprise topline Phase III trial results, pivotal efficacy study results, an expected patent expiration, and a meeting with the FDA.
- The overall likelihood of approval of a Phase I ADHD asset is 12.9%, and the average probability a drug advances from Phase III is 78.6%. Drugs, on average, take 8.9 years from Phase I to approval, compared to 8.8 years in the overall psychiatry space.
- There have been 21 licensing and asset acquisition deals involving ADHD drugs during 2014-19. Impax Laboratories' acquisition of certain assets related to generic products from Teva and Allergan in 2016 for $586m was the largest deal.
- The distribution of clinical trials across Phase I-IV indicates that the majority of trials for ADHD have been in the late phases of development, with 54% in Phase III-IV, and 46% in Phase I-II.
- The US has a substantial lead in the number of ADHD clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
- Clinical trial activity in the ADHD space is dominated by completed trials. Takeda has the highest number of completed clinical trials for ADHD, with 157 trials.
- Takeda leads the industry sponsors with the highest number of clinical trials for ADHD, followed by Eli Lilly and Johnson & Johnson
Key Topics Covered:
1. Overview
2. Key Takeaways
3. Disease Background
- Subtypes
4. Treatment
- Non-pharmacological therapy
- Pharmacological therapy
5. Epidemiology
6. Marketed Drugs
7. Pipeline Drugs
8. Recent Events and Analyst Opinion
- Multiple Drugs for ADHD (September 04, 2019)
- Vafidemstat for ADHD (April 25, 2019)
- Monarch eTNS system for ADHD (April 19, 2019)
- SPN-812 for ADHD (March 28, 2019)
- AEVI-001 for ADHD (January 02, 2019)
- SPN-812 for ADHD (December 20, 2018)
- SPN-812 for ADHD (December 06, 2018)
- Dasotraline for ADHD (August 31, 2018)
- KP415 for ADHD (July 9, 2018)
9. Key Upcoming Events
10. Key Regulatory Events
- NeuroSigma Monarch eTNS Becomes The First FDA-Cleared ADHD Device
- Approval of Vyvanse for Pediatric ADHD in Japan
- Adhansia XR Approval Boosts Purdue's Move Away From Opioids
11. Probability of Success
12. Licensing and Asset Acquisition Deals
- KemPharm Offloads Two ADHD Candidates To Gurnet Point
- Shionogi Licenses Akili's Digital Medicine Candidates For ADHD, ASD
13. Parent Patents
14. Revenue Opportunity
15. Clinical Trial Landscape
- Sponsors by status
- Sponsors by phase
- Recent events
16. Bibliography
Companies Mentioned
- Allergan
- Eli Lilly
- Johnson & Johnson
- Takeda
- Teva
For more information about this report visit https://www.researchandmarkets.com/r/kuerud
